Previous 10 | Next 10 |
It was a rough two years for Cathie Wood, but the Ark Invest founder, CEO, and money manager is bouncing back in 2023. Her family of growth-oriented exchange-traded funds is rolling again. Wood's transparency finds Ark announcing all of its daily transactions. She added to existing positions ...
Additional sequencing applications and reference standards to be highlighted at the conference Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - February 5, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is i...
Twist Bioscience Corp (TWST) Q1 2023 Earnings Conference Call February 03, 2023, 08:00 ET Company Participants Angela Bitting - Chief ESG Officer & SVP, Corporate Affairs Emily Leproust - Co-Founder, Chairman & CEO James Thorburn - CFO Conference Call Par...
Shares of Twist Bioscience (NASDAQ: TWST) were sinking 17.5% as of 11:18 a.m. ET on Friday. The steep decline came after the synthetic DNA maker announced its fiscal 2023 first-quarter results. Twist reported Q1 revenue of $54.2 million, up 29% year over year. This revenue total narro...
Twist Bioscience Corporation ( NASDAQ: TWST ) lost ~6% pre-market Friday after the maker of synthetic DNA products issued Q1 FY23 results setting its guidance for the second quarter below expectations. Thanks to $49M of combined SynBio revenue and NGS revenue, the company expe...
Twist Bioscience press release ( NASDAQ: TWST ): Q1 GAAP EPS of -$0.74 beats by $0.36 . Revenue of $54.24M (+29.1% Y/Y) misses by $0.23M . Q2 Outlook : Revenue is expected to be approximately $56.5M vs. consensus of $61.83M; Gross margin is expected to be 30%. ...
– Revenue of $54.2M in 1QFY23 increased 29% over $42.0M in 1QFY22 – – Orders increased to $64.7M in 1QFY23, an increase of 30% over 1QFY22 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of hig...
Twist Bioscience ( NASDAQ: TWST ) is scheduled to announce Q1 earnings results on Friday, February 3rd, before market open. The consensus EPS Estimate is -$1.17 (-28.6% Y/Y) and the consensus Revenue Estimate is $54.47M (+29.7% Y/Y). Over the last 2 years, TWST has beaten EP...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - February 1, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...